R&D News | pharmaphorum

News

ESMO: Trials end 20-year hiatus in cervical cancer therapy

Amid all the new high-tech therapies on display at the ESMO cancer conference, a study funded by Cancer Research UK has shown what can be achieved with cheap generic drugs

News

Rumour confirmed as Roche buys Telavant for $7.1bn

Roche has announced a $7.1 billion deal to acquire Roivant group company Telavant and its RVT-301 drug candidate for inflammatory bowel disease (IBD), confirming rumours t

News

ESMO: Immunotherapy combos extend lives in bladder cancer

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer.

News

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC

Roche’s Alecensa has become the first drug in the ALK inhibitor class to significantly improve disease-free survival across all disease stages in a phase 3 trial involving

News

ESMO: Opdivo chases Keytruda in perioperative lung cancer

Just days after MSD claimed an FDA approval for Keytruda as a pre- and post-surgery option for early non-small cell lung cancer (NSCLC), Bristol-Myers Squibb has staked a

News

Beam cuts one in five staffers to conserve cash

Gene-editing company Beam Therapeutics has shifted into reverse, slashing staff and R&D programmes after a period of expansion since its public debut in 2020.

ESMO: Trials end 20-year hiatus in cervical cancer therapy

Rumour confirmed as Roche buys Telavant for $7.1bn

ESMO: Immunotherapy combos extend lives in bladder cancer

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC

ESMO: Opdivo chases Keytruda in perioperative lung cancer

Beam cuts one in five staffers to conserve cash

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks